Evidence map›Paper›PMID 38296474›Full record

ArticleInternal medicine (Tokyo, Japan)2024

Successful Treatment of Malignant Lymphoma Following Transcatheter Aortic Valve Replacement.

Takumi Osawa, Kazuko Tajiri, Tomoya Hoshi, Masaki Ieda, Tomoko Ishizu

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Takumi OsawaDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Japan.
Kazuko TajiriDepartment of Cardiology, National Cancer Center Hospital East, Japan.
Tomoya HoshiDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Japan.
Masaki IedaDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Japan.
Tomoko IshizuDepartment of Cardiology, Institute of Medicine, University of Tsukuba, Japan.
University of Tsukuba · JPNational Cancer Center Hospital East · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 67-year-old woman with severe aortic stenosis (AS) was transferred to our hospital for large B-cell lymphoma treatment. Because of her high risk of anthracycline-induced cardiotoxicity due to severe AS and low performance status, the patient was initially treated with doxorubicin-free chemotherapy. However, doxorubicin was considered necessary to achieve complete remission. After multidisciplinary team discussions, transcatheter aortic valve replacement (TAVR) was performed without complications. Nine days after TAVR, the patient received the first cycle of anthracycline-containing chemotherapy (R-CHOP). Currently, 12 months after completing 4 cycles of R-CHOP, the patient remains in complete remission without having developed cardiotoxicity.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAortic Valve StenosisCyclophosphamideDoxorubicinLymphoma, Large B-Cell, DiffusePrednisoneRituximabTranscatheter Aortic Valve ReplacementVincristineAgedFemaleHumansRemission InductionTreatment OutcomeCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineanthracyclineaortic stenosiscardio-oncologyonco-cardiologyTAVITAVR

Identifiers

PMID38296474
PMCPMC11442919
OpenAlexW4391378627

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.